Plant
Cirrus Therapeutics Raises $11M to Advance Gene Therapy Targeting Dry Age-Related Macular Degeneration
Cirrus Therapeutics; gene therapy; dry AMD; IRAK-M; AAV; seed funding; ocular immunology; vision loss
Novo Nordisk Terminates $598M Heart Failure Cell Therapy Collaboration with Heartseed Amid Major Restructuring
Novo Nordisk; Heartseed; heart failure; cell therapy; HS-001; collaboration termination; strategic restructuring; Maziar Mike Doustdar; diabetes; obesity; biotechnology
FDA Issues Warning Letter to J&J Subsidiary Over Stopper Issues and Quality Reporting at Korean Plant
FDA warning letter; Johnson & Johnson subsidiary; Janssen Vaccines; Korean production plant; vial stopper defects; quality control violations; spotty complaint reporting; good manufacturing practices; Incheon; pharmaceutical manufacturing
Bayer-allied NextRNA Therapeutics winds down operations after missing a milestone in their collaboration
NextRNA Therapeutics; Bayer; lncRNA; long non-coding RNA; oncology; biotech wind-down; missed milestone; Massachusetts biotech; seed and Series A funding; Dana-Farber; Carl Novina; 2025 biotech shutdowns
Trump Administration Unveils Health Data Sharing Scheme Backed by Apple, Amazon, and Others
Trump administration; health data sharing; CMS Interoperability Framework; Apple; Amazon; digital health records; patient data; privacy; tech partnerships
UnitedHealth Group Names Mike Cotton as New Medicaid CEO in Executive Reshuffle
UnitedHealth Group; CEO appointment; Medicaid; Mike Cotton; executive changes; government programs; Bobby Hunter; leadership transition
Lilly backs $65M raise for biotech plumbing the ‘dark genome’ with AI
Haya, Eli Lilly, Genome, Long Intergenic Non-Protein Coding RNA, Obesity, Aortic Valve Insufficiency, Eli, Dark color
Vanda Escalates Vendetta Against FDA, Blasts Bureaucrats for Delaying Stomach Drug
United States Food and Drug Administration, Vanda, United States Food and Drug Administration, Gastroparesis, Translucent
Cassava Sciences Discontinues Alzheimer’s Program After Simufilam Fails Second Phase 3 Trial
Cassava Sciences, simufilam, Alzheimer’s disease, Phase 3 trial failure, drug development discontinuation